{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:38:53Z","timestamp":1790451533108,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81671757"],"award-info":[{"award-number":["81671757"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901813"],"award-info":[{"award-number":["81901813"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}]},{"name":"Beijing Hope Run Special Fund of the Cancer Foundation of China","award":["LC2016B07"],"award-info":[{"award-number":["LC2016B07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To evaluate proton-density fat-fraction (PDFF) and intravoxel incoherent motion (IVIM) techniques, and human 25-hydroxyvitamin D3 (25OH-VitD3) levels, as potential biomarkers in patients with colorectal cancer with liver metastasis (CRCLM). Changes were compared with those related to chemotherapy-associated steatohepatitis (CASH) and sinusoidal obstruction syndrome (SOS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>63 patients with pathologically confirmed colorectal adenocarcinoma received 4\u20136 courses of NC before liver resection and underwent magnetic resonance imaging (MRI) with iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantification and IVIM sequences. Blood samples were analyzed using CTCAE. Pathological changes of liver tissues outside the metastases were assessed as the gold standard, and receiver operating characteristic (ROC) curves were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>16 cases had CASH liver injury, 14 cases had SOS changes, and 4 cases had CASH and SOS, and 7 showed no significant changes. Consistency between biochemical indices and pathological findings was poor (<jats:italic>kappa<\/jats:italic>\u00a0=\u20090.246,<jats:italic>p<\/jats:italic>\u00a0=\u20090.005). The areas under the ROC curve (AUCs) of ALT, AST, ALP, GGT, and TBIL were 0.571\u20130.691. AUCs of D, FF, and 25OH-VitD3 exceeded 0.8; when considering these markers together, sensitivity was 85.29% and specificity was 93.13%. ANOVA showed statistically significant differences among<jats:italic>D<\/jats:italic>, FF, and 25OH-VitD3 for different grades of liver injury (<jats:italic>F<\/jats:italic>\u00a0=\u20094.64\u201326.5,<jats:italic>p<\/jats:italic>\u00a0=\u20090.000\u20130.016).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:italic>D<\/jats:italic>, FF, and 25OH-VitD3 are biomarkers for accurate prediction of NC-induced liver injury in patients with CRCLM, while FF and 25OH-VitD3 might be beneficial to distinguish liver injury grades.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Current Trials was retrospectively registered as<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/edit.aspx?pid=25998&amp;htm=4\">ChiCTR1800015242<\/jats:ext-link>at Chinese Clinical Trial Registry on March 16, 2018.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-07282-6","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T07:02:37Z","timestamp":1597474957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Quantified MRI and 25OH-VitD3 can be used as effective biomarkers for patients with neoadjuvant chemotherapy-induced liver injury in CRCLM?"],"prefix":"10.1186","volume":"20","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,15]]},"reference":[{"key":"7282_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.hpb.2017.11.007","volume":"20","author":"A Sultana","year":"2018","unstructured":"Sultana A, Brooke-Smith M, Ullah S, et al. Prospective evaluation of the international study Group for Liver Surgery definition of post hepatectomy liver failure after liver resection: an international multicentre study. HPB. 2018;20:462\u20139.","journal-title":"HPB"},{"key":"7282_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.hpb.2016.03.001","volume":"18","author":"E Khoo","year":"2016","unstructured":"Khoo E, O'Neill S, Brown E, Wigmore SJ, Harrison EM. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB. 2016;18:485\u201393.","journal-title":"HPB"},{"key":"7282_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","volume":"371","author":"B Nordlinger","year":"2008","unstructured":"Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007\u201316.","journal-title":"Lancet"},{"key":"7282_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","volume":"14","author":"B Nordlinger","year":"2013","unstructured":"Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208\u201315.","journal-title":"Lancet Oncol"},{"key":"7282_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ejso.2013.04.002","volume":"39","author":"RP Jones","year":"2013","unstructured":"Jones RP, Malik HZ, Fenwick SW, Poston GJ. Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur J Surg Onc. 2013;39:807\u201311.","journal-title":"Eur J Surg Onc"},{"key":"7282_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12957-018-1322-9","volume":"16","author":"K-M Chan","year":"2018","unstructured":"Chan K-M, Wu T-H, Wang Y-C, et al. Clinical relevance of oncologic prognostic factors in the decision-making of pre-hepatectomy chemotherapy for colorectal cancer hepatic metastasis: the priority of hepatectomy. World J Surg Oncol. 2018;16:24\u201332.","journal-title":"World J Surg Oncol"},{"key":"7282_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1477-2574.2012.00557.x","volume":"15","author":"RB Adams","year":"2013","unstructured":"Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB. 2013;15:91\u2013103.","journal-title":"HPB"},{"key":"7282_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3748\/wjg.v22.i2.567","volume":"22","author":"RE Mattar","year":"2016","unstructured":"Mattar RE, Al-Alem FA, Simoneau E, Hassanain M. Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World J Gastroenterol. 2016;22:567\u201381.","journal-title":"World J Gastroenterol"},{"key":"7282_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1477-2574.2012.00597.x","volume":"15","author":"EK Abdalla","year":"2013","unstructured":"Abdalla EK, Bauer TW, Chun YS, D'Angelica M, Kooby DA, Jarnagin WR. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB. 2013;15:119\u201330.","journal-title":"HPB"},{"key":"7282_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.critrevonc.2013.05.011","volume":"88","author":"D McWhirter","year":"2013","unstructured":"McWhirter D, Kitteringham N, Jones RP, Malik H, Park K, Palmer D. Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes. Crit Rev Oncol Hemat. 2013;88:404\u201315.","journal-title":"Crit Rev Oncol Hemat"},{"key":"7282_CR11","doi-asserted-by":"crossref","unstructured":"Bahirwani R, Reddy KR (2104) Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 34:162\u2013171.","DOI":"10.1055\/s-0034-1375957"},{"key":"7282_CR12","doi-asserted-by":"crossref","unstructured":"Thatishetty AV, Agresti N, O'Brien CB (2013) Chemotherapy-induced hepatotoxicity. Clin liver dis 17:671-686; ix-x.","DOI":"10.1016\/j.cld.2013.07.010"},{"key":"7282_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00520-010-1078-4","volume":"20","author":"B Vincenzi","year":"2012","unstructured":"Vincenzi B, Daniele S, Frezza AM, et al. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer. 2012;20:135\u20139.","journal-title":"Support Care Cancer"},{"key":"7282_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3816\/CCC.2009.n.038","volume":"8","author":"JH Slade","year":"2009","unstructured":"Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009;8:225\u201330.","journal-title":"Clin Colorectal Cancer"},{"key":"7282_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00210-014-0994-0","volume":"387","author":"TE Schwingel","year":"2014","unstructured":"Schwingel TE, Klein CP, Nicoletti NF, et al. Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice. N-S Arch Pharmacol. 2014;387:837\u201348.","journal-title":"N-S Arch Pharmacol"},{"key":"7282_CR16","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.ejso.2017.05.008","volume":"43","author":"G Duwe","year":"2017","unstructured":"Duwe G, Knitter S, Pesthy S, et al. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. Eur J Surg Onc. 2017;43:1668\u201381.","journal-title":"Eur J Surg Onc"},{"key":"7282_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1067\/j.cpsurg.2017.10.002","volume":"54","author":"J Chakedis","year":"2017","unstructured":"Chakedis J, Squires MH, Beal EW, et al. Update on current problems in colorectal liver metastasis. Curr Prob Surg. 2017;54:554\u2013602.","journal-title":"Curr Prob Surg"},{"key":"7282_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/hpb.12007","volume":"15","author":"E Parkin","year":"2013","unstructured":"Parkin E, O'Reilly DA, Adam R, et al. The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. HPB. 2013;15:463\u201372.","journal-title":"HPB"},{"key":"7282_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1477-7819-11-65","volume":"11","author":"D Takeda","year":"2013","unstructured":"Takeda D, Nitta H, Takahara T, Hasegawa Y, Itou N, Wakabayashi G. Effect of preoperative chemotherapy on postoperative liver regeneration following hepatic resection as estimated by liver volume. World J Surg Oncol. 2013;11:65.","journal-title":"World J Surg Oncol"},{"key":"7282_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijsu.2018.01.042","volume":"52","author":"AS Khan","year":"2018","unstructured":"Khan AS, Garcia-Aroz S, Ansari MA, et al. Assessment and optimization of liver volume before major hepatic resection: current guidelines and a narrative review. Int J Surg. 2018;52:74\u201381.","journal-title":"Int J Surg"},{"issue":"48","key":"7282_CR21","doi-asserted-by":"publisher","first-page":"18131","DOI":"10.3748\/wjg.v20.i48.18131","volume":"20","author":"M Soresi","year":"2014","unstructured":"Soresi M, Giannitrapani L, Cervello M, et al. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol. 2014;20(48):18131\u201350.","journal-title":"World J Gastroenterol"},{"key":"7282_CR22","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00330-011-2333-x","volume":"22","author":"NY Shin","year":"2012","unstructured":"Shin NY, Kim MJ, Lim JS, et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol. 2012;22:864\u201371.","journal-title":"Eur Radiol"},{"key":"7282_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejrad.2017.12.016","volume":"100","author":"ZQ Huang","year":"2018","unstructured":"Huang ZQ, Yang HF, Lin WL, Xu L. Re: diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: radio-pathological correlation. Eur J Radiol. 2018;100:154.","journal-title":"Eur J Radiol"},{"key":"7282_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejrad.2018.01.019","volume":"100","author":"S Cayet","year":"2018","unstructured":"Cayet S. Re: diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: radio-pathological correlation. Eur J Radiol. 2018;100:155.","journal-title":"Eur J Radiol"},{"key":"7282_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.cgh.2017.01.009","volume":"15","author":"X Li","year":"2017","unstructured":"Li X, Yang XQ, Xu D, et al. Magnetic resonance imaging findings in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Clin Gastroenterol Hepatol. 2017;15:955\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7282_CR26","doi-asserted-by":"crossref","unstructured":"Ha Y, Hwang SG, Rim KS (2017) The association between vitamin d insufficiency and nonalcoholic fatty liver disease: a population-based study. Nutrients, 9: pii: E806.","DOI":"10.3390\/nu9080806"},{"key":"7282_CR27","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.ejrad.2011.02.065","volume":"81","author":"E Hijona","year":"2012","unstructured":"Hijona E, Sanchez-Gonzalez J, Alustiza JM, et al. Accurate fat-fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5 T in rats with nonalcoholic fatty liver disease. Eur J Radiol. 2012;81:1122\u20137.","journal-title":"Eur J Radiol"},{"key":"7282_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113846","volume":"9","author":"PX Lu","year":"2014","unstructured":"Lu PX, Huang H, Yuan J, et al. Decreases in molecular diffusion, perfusion fraction and perfusion-related diffusion in fibrotic livers: a prospective clinical intravoxel incoherent motion MR imaging study. PLoS One. 2014;9:e113846.","journal-title":"PLoS One"},{"key":"7282_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/jmri.22081","volume":"31","author":"J Patel","year":"2010","unstructured":"Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging. 2010;31:589\u2013600.","journal-title":"J Magn Reson Imaging"},{"key":"7282_CR30","unstructured":"Parente DB, Paiva FF, Neto JAO, et al (2015) Intravoxel incoherent motion diffusion weighted MR imaging at 3.0 t: assessment of steatohepatitis and fibrosis compared with liver biopsy in type 2 diabetic patients. Plos one 10: e0125653."},{"key":"7282_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/mrm.25109","volume":"73","author":"AD Cohen","year":"2015","unstructured":"Cohen AD, Schieke MC, Hohenwalter MD, Schmainda KM. The effect of low b-values on the intravoxel incoherent motion derived pseudodiffusion parameter in liver. Magn Reson Med. 2015;73:306\u201311.","journal-title":"Magn Reson Med"},{"key":"7282_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139874","volume":"10","author":"SM Yu","year":"2015","unstructured":"Yu SM, Ki SH, Baek HM. Nonalcoholic fatty liver disease: correlation of the liver parenchyma fatty acid with intravoxel incoherent motion MR imaging-an experimental study in a rat model. PLoS One. 2015;10:e0139874.","journal-title":"PLoS One"},{"key":"7282_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12094-013-1104-3","volume":"16","author":"MLG Dorronsoro","year":"2014","unstructured":"Dorronsoro MLG, Vera R, Ortega L, et al. Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy. Clin Transl Oncol. 2014;16:234\u201342.","journal-title":"Clin Transl Oncol"},{"key":"7282_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1245\/s10434-009-0781-1","volume":"17","author":"TC Chua","year":"2010","unstructured":"Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol. 2010;17:492\u2013501.","journal-title":"Ann Surg Oncol"},{"key":"7282_CR35","doi-asserted-by":"publisher","first-page":"E141","DOI":"10.1016\/j.clcc.2016.03.007","volume":"15","author":"D Sabanathan","year":"2016","unstructured":"Sabanathan D, Eslick GD, Shannon J. Use of neoadjuvant chemotherapy plus molecular targeted therapy in colorectal liver metastases: a systematic review and meta-analysis. Clin Colorectal Canc. 2016;15:E141\u20137.","journal-title":"Clin Colorectal Canc"},{"key":"7282_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.hpb.2017.08.008","volume":"20","author":"P Gavriilidis","year":"2018","unstructured":"Gavriilidis P, Sutcliffe RP, Hodson J, Marudanayagam R, et al. Simultaneous versus delayed hepatectomy for synchronous colorectal liver metastases: a systematic review and meta-analysis. HPB. 2018;20:11\u20139.","journal-title":"HPB"},{"key":"7282_CR37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.ejso.2016.08.019","volume":"43","author":"M Okuno","year":"2017","unstructured":"Okuno M, Hatano E, Nishino H, Seo S, Taura K, Uemoto S. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: a systematic review. Ejso-Eur J Surg Onc. 2017;43:1003\u201312.","journal-title":"Ejso-Eur J Surg Onc"},{"key":"7282_CR38","first-page":"187","volume":"28","author":"NJ Wang","year":"2018","unstructured":"Wang NJ, Chen C, Zhao L, et al. Vitamin D and nonalcoholic fatty liver disease: bi-directional mendelian randomization analysis. E-BioMedicine. 2018;28:187\u201393.","journal-title":"E-BioMedicine"},{"key":"7282_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.21037\/qims.2017.02.03","volume":"7","author":"YT Li","year":"2017","unstructured":"Li YT, Cercueil JP, Yuan J, Chen WT, Loffroy R, Wang YXJ. Liver intravoxel incoherent motion (IVIM) magnetic resonance imaging: a comprehensive review of published data on normal values and applications for fibrosis and tumor evaluation. Quant Imaging Med Surg. 2017;7:59\u201378.","journal-title":"Quant Imaging Med Surg"},{"key":"7282_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1148\/radiol.2015141974","volume":"278","author":"I Joo","year":"2016","unstructured":"Joo I, Lee JM, Grimm R, Han JK, Choi BI. Monitoring vascular disrupting therapy in a rabbit liver tumor model: relationship between tumor perfusion parameters at IVIM diffusion-weighted MR imaging and those at dynamic contrast-enhanced MR imaging. Radiology. 2016;278:104\u201313.","journal-title":"Radiology"},{"key":"7282_CR41","doi-asserted-by":"publisher","first-page":"W26","DOI":"10.2214\/AJR.15.15683","volume":"207","author":"JH Kim","year":"2016","unstructured":"Kim JH, Joo I, Kim TY, et al. Diffusion-related MRI parameters for assessing early treatment response of liver metastases to cytotoxic therapy in colorectal cancer. Am J Roentgenol. 2016;207:W26\u201332.","journal-title":"Am J Roentgenol"},{"key":"7282_CR42","doi-asserted-by":"publisher","first-page":"20160140","DOI":"10.1259\/bjr.20160140","volume":"89","author":"Y Kim","year":"2016","unstructured":"Kim Y, Ko K, Kim D, et al. Intravoxel incoherent motion diffusion-weighted MR imaging of breast cancer: association with histopathological features and subtypes. Brit J Radiol. 2016;89:20160140.","journal-title":"Brit J Radiol"},{"key":"7282_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000485180","volume":"97","author":"M Jamka","year":"2018","unstructured":"Jamka M, Arslanow A, Bohner A, et al. Effects of gene variants controlling vitamin d metabolism and serum levels on hepatic steatosis. Digestion. 2018;97:298\u2013308.","journal-title":"Digestion"},{"key":"7282_CR44","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/jgh.13326","volume":"31","author":"A Facciorusso","year":"2016","unstructured":"Facciorusso A, Del Prete V, Muscatiello N, Crucinio N, Barone M. Prognostic role of 25-hydroxyvitamin D in patients with liver metastases from colorectal cancer treated with radiofrequency ablation. J Gastroen Hepatol. 2016;31:1483\u20138.","journal-title":"J Gastroen Hepatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07282-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07282-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07282-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T01:26:22Z","timestamp":1667784382000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07282-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7282"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07282-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This single-center retrospective study was approved by China cancer foundation ethics committee and the need for written informed consent was waived. Approval was registered under local number NCC2016YQ-17.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"767"}}